Key result
ACKR3/CXCR7 exerts anti-thrombotic platelet effects unlike CXCR4 and represents a potential therapeutic target post-MI.
Why the study?
To review the differential roles and trafficking of CXCR4 and ACKR3/CXCR7 in regulating thrombo-inflammatory platelet functions, and the potential of ACKR3/CXCR7 as an anti-thrombotic strategy post-MI.
The review highlights the anti-thrombotic potential of targeting the atypical chemokine receptor ACKR3/CXCR7 in platelet-associated cardiovascular disorders, particularly post-MI.
May support ACKR3 as anti-thrombotic target post-MI; leaves open validation in prospective trials.
The manifold actions of the pro-inflammatory and regenerative chemokine CXCL12/SDF-1α are executed through the canonical GProteinCoupledReceptor CXCR4, and the non-canonical ACKR3/CXCR7. Platelets express CXCR4, ACKR3/CXCR7, and are a vital source of CXCL12/SDF-1α themselves. In recent years, a regulatory impact of the CXCL12-CXCR4-CXCR7 axis on platelet biogenesis i.e. megakaryopoiesis, thrombotic and thrombo-inflammatory ac-tions have been revealed through experimental and clinical studies. Platelet surface expression of ACKR3/CXCR7 is significantly enhanced following myocardial infarction (MI) in acute coro-nary syndrome (ACS) patients, also associated with improved functional recovery and progno-sis. The therapeutic implications of ACKR3/CXCR7 in myocardial regeneration and improved recovery following an ischemic episode, are well documented. Cardiomyocytes, cardi-ac-fibroblasts, endothelial lining of the blood vessels perfusing the heart, besides infiltrating platelets and monocytes, all express ACKR3/CXCR7. This review recapitulates ligand induced differential trafficking of platelet CXCR4-ACKR3/CXCR7 affecting their surface availability, and in regulating thrombo-inflammatory platelet functions and survival through CXCR4 or ACKR3/CXCR7. It emphasizes the pro-thrombotic influence of CXCL12/SDF-1α exerted through CXCR4, as opposed to the anti-thrombotic impact of ACKR3/CXCR7. Offering an innovative translational perspective, this review also discusses the advantages and challenges of utilizing ACKR3/CXCR7 as a potential anti-thrombotic strategy in platelet associated cardiovascular dis-orders, particularly in coronary artery disease (CAD) patients post-MI.
No takes yet. Share an insight, caveat, or question.
Madhumita Chatterjee (2021) conducted a review in Coronary artery disease (CAD) post-myocardial infarction. ACKR3/CXCR7 targeted therapy was evaluated. The chemokine receptor ACKR3/CXCR7 exerts an anti-thrombotic impact on platelets, contrasting with the pro-thrombotic influence of CXCR4, and represents a potential therapeutic target post-MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: